Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brivanib in Persistent or Recurrent Cervical Cancer
NCT01267253Phase 2Completed
- Sponsor
- GOG Foundation
- Start
- Apr 2011
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brivanib alaninate in Cervical Cancer (CC), sponsored by GOG Foundation. Primary endpoints: Proportion of Patients Progression-Free for at Least 6 Months, Objective Tumor Response up to 2 years and 1 more. Started Apr 2011; status: completed.
02
Drugs
brivanib alaninate
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT01267253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01267253.